PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
树突状细胞亚群在开发用于癌症治疗的个性化免疫疗法中的潜力
英文原题：The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.
查看英文原题
The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自1973年Ralph Steinman发现树突状细胞（DC）以来，关于这些固有免疫细胞的知识大量积累。它们在调节固有免疫和适应性免疫过程中的作用正逐渐被揭示。DC是高效的抗原提呈细胞，能够激活初始T淋巴细胞，从而启动并产生有效的抗肿瘤反应。尽管基于DC的免疫治疗尚未取得显著成果，但大量正在进行的临床试验凸显了DC疫苗的相关性，尤其是作为辅助治疗或与其他治疗方案联合使用。本综述概述了目前关于人类DC的知识、其分类以及不同DC群体的功能。讨论了开发用于治疗肿瘤疾病的治疗性DC疫苗的逐步过程，并对联合治疗方法的潜力以及DC疫苗在现代免疫治疗中的作用进行了推测。
展开英文摘要原文
Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous amount of knowledge regarding these innate immunity cells has been accumulating. Their role in regulating both innate and adaptive immune processes is gradually being uncovered. DCs are proficient antigen-presenting cells capable of activating naive T-lymphocytes to initiate and generate effective anti-tumor responses.
Although DC-based immunotherapy has not yielded significant results, the substantial number of ongoing clinical trials underscores the relevance of DC vaccines, particularly as adjunctive therapy or in combination with other treatment options.
This review presents an overview of current knowledge regarding human DCs, their classification, and the functions of distinct DC populations. The stepwise process of developing therapeutic DC vaccines to treat oncological diseases is discussed, along with speculation on the potential of combined therapy approaches and the role of DC vaccines in modern immunotherapy.
论文信息
- 作者
- Gorodilova AV、Kitaeva KV、Filin IY、Mayasin YP、Kharisova CB、Issa SS、Solovyeva VV、Rizvanov AA
- 单位
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.Russia
- 文献类型
- 综述
- 期刊
- Current issues in molecular biology2023 Oct 1
- 原文标识
- PubMed 37886952 · DOI 10.3390/cimb45100509
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →